{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T19:10:42Z","timestamp":1648581042547},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.arteri.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T12:31:27Z","timestamp":1531830687000},"page":"240-247","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uso de la polip\u00edldora cardiovascular 40 mg en prevenci\u00f3n cardiovascular secundaria"],"prefix":"10.1016","volume":"30","author":[{"given":"Domingo","family":"Marzal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Rodr\u00edguez Padial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan-Albert","family":"Arn\u00e1iz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cos\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki","family":"Lekuona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2018.04.004_bib0170","unstructured":"Instituto Nacional de Estad\u00edstica. Defunciones seg\u00fan causa de muerte 2016, [consultado 26 Mar 2018]. Disponible en: http:\/\/www.ine.es\/jaxi\/Tabla.htm?path=\/t15\/p417\/a2016\/l0\/&file=01000.px&L=0; 2017.."},{"key":"10.1016\/j.arteri.2018.04.004_bib0175","first-page":"472","article-title":"Epidemiology of acute coronary syndromes in Spain: estimation of the number of cases and trends from 2005 to 2049","volume":"66","author":"Degano","year":"2013","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.arteri.2018.04.004_bib0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","article-title":"Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study","volume":"55","author":"Kannel","year":"1961","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.arteri.2018.04.004_bib0185","first-page":"1","article-title":"Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study","volume":"30","author":"Morales","year":"2018","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2018.04.004_bib0190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/STROKEAHA.109.566950","article-title":"Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke","volume":"41","author":"Glader","year":"2010","journal-title":"Stroke."},{"key":"10.1016\/j.arteri.2018.04.004_bib0195","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10557-007-6040-4","article-title":"Predictors of adherence to statins for primary prevention","volume":"21","author":"Mann","year":"2007","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.arteri.2018.04.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med."},{"key":"10.1016\/j.arteri.2018.04.004_bib0205","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0210","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.04.004_bib0215","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2013.277064","article-title":"Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial","volume":"310","author":"Thom","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.04.004_bib0220","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g3318","article-title":"Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care","volume":"348","author":"Selak","year":"2014","journal-title":"BMJ."},{"key":"10.1016\/j.arteri.2018.04.004_bib0225","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1177\/2047487314530382","article-title":"A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk","volume":"22","author":"Patel","year":"2015","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0230","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0235","article-title":"Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases","volume":"3","author":"Bahiru","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.arteri.2018.04.004_bib0240","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.04.004_bib0245","volume":"23","author":"Authors\/Task Force M.","year":"2016","journal-title":"Eur J Prev Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0250","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.medcli.2016.10.031","article-title":"Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease","volume":"148","author":"Gonzalez-Juanatey","year":"2017","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.arteri.2018.04.004_bib0255","first-page":"547","article-title":"A step ahead in secondary prevention of cardiovascular risk. consensus document on clinical use of the polypill","volume":"69","author":"Gonzalez-Juanatey","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"10.1016\/j.arteri.2018.04.004_bib0260","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.04.004_bib0265","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.arteri.2018.04.004_bib0270","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens."},{"key":"10.1016\/j.arteri.2018.04.004_bib0275","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al., 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017:pii: HYP. 0000000000000065.","DOI":"10.22141\/2307-1257.7.1.2018.122220"},{"key":"10.1016\/j.arteri.2018.04.004_bib0280","doi-asserted-by":"crossref","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-8.","DOI":"10.1016\/0140-6736(93)92693-N"},{"key":"10.1016\/j.arteri.2018.04.004_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2018.04.004_bib0290","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0295","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke."},{"key":"10.1016\/j.arteri.2018.04.004_bib0300","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.04.004_bib0305","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.arteri.2018.04.004_bib0310","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2018.04.004_bib0315","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(17)30553-6","article-title":"Uses of polypills for cardiovascular disease and evidence to date","volume":"389","author":"Huffman","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.arteri.2018.04.004_bib0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jgs.14682","article-title":"Clinical outcomes associated with medication regimen complexity in older people: A systematic review","volume":"65","author":"Wimmer","year":"2017","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.arteri.2018.04.004_bib0325","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40266-014-0163-7","article-title":"Medication non-adherence among elderly patients newly discharged and receiving polypharmacy","volume":"31","author":"Pasina","year":"2014","journal-title":"Drugs Aging."},{"key":"10.1016\/j.arteri.2018.04.004_bib0330","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J."}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916818300524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T22:47:12Z","timestamp":1571611632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916818300524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0214916818300524"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2018.04.004","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uso de la polip\u00edldora cardiovascular 40mg en prevenci\u00f3n cardiovascular secundaria","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}